Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to

Latest news

More from news
Approximately 163 fully matching, plus 361 partially matching documents found.

Latest Intelligence

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    Danny Buckland interviews Gilead’s Mike Elliott. The hard-earned lessons and multiple setbacks that characterised the fight to control HIV could provide a template for tackling the fast-advancing public ... their big budget spreadsheets,” said Mike

  • The Golden Goose The Golden Goose

    In 2014 when Gilead tried to launch Sovaldi and Harvoni in the UK, the NHS, concerned it would be unable to budget for the expensive drugs, delayed bringing them to market. .

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The Belgian-. Dutch company broke through to a new level in July this year when it signed a remarkable $5.1bn R&D

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    NHS England judged Gilead’s offer to be the best, giving it a‘Gold’ partner status. ... it. Gilead has been working with drug treatment services, prisons and building expertise since 2013.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).

More from intelligence
Approximately 4 fully matching, plus 43 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics